SLXN Stock Summary and Trading Ideas (Silexion Therapeutics - | NASDAQ:SLXN)

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.

Silexion Therapeutics - trades on the NASDAQ stock market under the symbol SLXN.

As of July 2, 2026, SLXN stock price climbed to $2.64 with 30,543 million shares trading.

SLXN has a beta of 1.48, meaning it tends to be more sensitive to market movements. SLXN has a correlation of 0.02 to the broad based SPY ETF.

SLXN has a market cap of $2.81 million. This is considered a Sub-Micro Cap stock.

SLXN has underperformed the market in the last year with a price return of -97.8% while the SPY ETF gained +21.8%. SLXN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.3% and -8.8%, respectively, while the SPY returned +14.0% and +1.0%, respectively.

SLXN support price is $2.32 and resistance is $2.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLXN shares will trade within this expected range on the day.